Ipsen will consider requests for funding to Healthcare Organizations (HCOs), Patient Organizations (POs) and other not-for-profit third parties to support scientific, educational, and research relating to epidemiology, diagnosis, and/or treatment in the following areas:
Rare Disease
- Pituitary disease, including acromegaly
- Hormonal dysfunction, including severe primary IGF-1 deficiency (SPIGFD)
- Fibrodysplasia ossificans progressiva (FOP)
- Primary Biliary Cholangitis (PBC)
- Progressive familial intrahepatic cholestasis (PFIC)
- Alagille syndrome
- Biliary atresia
Neuroscience
- Cervical dystonia and other dystonic disorders
- Spasticity
- Other movement disorders
Oncology
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Carcinoid syndrome
- Pancreatic cancer
- Epithelioid Sarcoma
- Follicular Lymphoma
Grant approvals are not connected to or conditioned upon the purchasing, prescribing, providing favorable recommendations for, or otherwise supporting Ipsen products. The funding of a grant request does not impose an obligation, expressed or implied, on the recipient to purchase, prescribe, provide favorable formulary status for, or otherwise support Ipsen products. Formal notifications of grant awards will be made in writing to the applicant organization and supersede any prior oral or written understandings or communications between the applicant and Ipsen.
Grant requests will be reviewed by Ipsen’s Grant Review Committees on the basis of scientific and medical criteria.
For more information contact us at corporate.communications@ipsen.com